Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICLE 2022 | Measuring cell avidity to assess the efficacy of T-cell therapies

Yotam Bar-Ephraim • 1 Apr 2022
ICLE 2022
General CAR-NK CAR-T

Cell avidity is defined as the binding strength between two cells, and is vital the development of immunotherapies as it is a way to measure how efficacious the therapies are at binding to their target cells. Yotam Bar-Ephraim, PhD, LUMICKS, Amsterdam, The Netherlands, discusses techniques to measure cell avidity to determine the efficacy of various T-cell therapies such as chimeric antigen receptor (CAR)-T and natural killer (NK) cell therapies. The z-Movi instrument measures the strength of the immunological synapse between the target cell and the T-cell. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.

More from Yotam Bar-Ephraim

2:41
Cell avidity as a predictor of T-cell efficacy
Yotam Bar-Ephraim • 1 Apr 2022
1:04
Remaining challenges in improving T-cell therapies for cancer
Yotam Bar-Ephraim • 1 Apr 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals